Tokyo Tape
Sign in
← Otsuka Holdings

Annual report

4578.TEDINET S100T6VU
Period2023-01-01 → 2023-12-31
Filed2024-03-29
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥1.74T2022-01-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥1.50T2021-01-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.42T2020-01-01 → 2020-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.40T2019-01-01 → 2019-12-31dCons.Revenue IFRS (5-year summary)
Operating income¥139.6bn2023-01-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥150.3bn2022-01-01 → 2022-12-31Cons.Operating profit loss IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥173.0bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥163.6bn2021-01-01 → 2021-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥190.0bn2020-01-01 → 2020-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥173.5bn2019-01-01 → 2019-12-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥133.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥125.5bn2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥148.1bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥127.2bn2019-01-01 → 2019-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥125.5bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥137.3bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.10Tat 2022-12-31Cons.Assets IFRS
Total assets¥2.82Tat 2021-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.63Tat 2020-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.58Tat 2019-12-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥840.3bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31dCons.Equity IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.23Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.01Tat 2021-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.85Tat 2020-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.77Tat 2019-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥356.9bnat 2020-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥334.0bnat 2019-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥211.8bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥228.9bn2021-01-01 → 2021-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥232.8bn2020-01-01 → 2020-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥192.6bn2019-01-01 → 2019-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.6bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥95.3bn2021-01-01 → 2021-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥99.9bn2020-01-01 → 2020-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥52.3bn2019-01-01 → 2019-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.5bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.8bn2021-01-01 → 2021-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥104.9bn2020-01-01 → 2020-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥89.3bn2019-01-01 → 2019-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥246.82022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥231.322021-01-01 → 2021-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥273.152020-01-01 → 2020-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥234.552019-01-01 → 2019-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥224.12023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥246.782022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥231.152021-01-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥272.352020-01-01 → 2020-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥231.132019-01-01 → 2019-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥4,410.8at 2023-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,100.84at 2022-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,707.64at 2021-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,415.54at 2020-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,257.17at 2019-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.3%at 2021-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.5%at 2020-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.4%at 2019-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE5.3%2023-01-01 → 2023-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE6.3%2022-01-01 → 2022-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE6.5%2021-01-01 → 2021-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE8.2%2020-01-01 → 2020-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE7.3%2019-01-01 → 2019-12-31dCons.Rate of return on equity IFRS (5-year summary)
Employees34,388at 2023-12-31Cons.Number of employees
Employees33,482at 2022-12-31Cons.Number of employees
Employees33,226at 2021-12-31dCons.Number of employees
Employees33,151at 2020-12-31dCons.Number of employees
Employees32,992at 2019-12-31dCons.Number of employees
Revenue¥82.4bn2023-01-01 → 2023-12-31StandaloneOperating revenue1
Revenue¥57.0bn2022-01-01 → 2022-12-31StandaloneOperating revenue1
Revenue¥115.0bn2021-01-01 → 2021-12-31dStandaloneOperating revenue1 (5-year summary)
Revenue¥102.7bn2020-01-01 → 2020-12-31dStandaloneOperating revenue1 (5-year summary)
Revenue¥66.2bn2019-01-01 → 2019-12-31dStandaloneOperating revenue1 (5-year summary)
Operating income¥69.0bn2023-01-01 → 2023-12-31StandaloneOperating income
Operating income¥44.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income¥70.0bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥46.4bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income¥104.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥93.5bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥57.8bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥70.0bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax¥46.0bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income¥71.0bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥47.4bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income¥106.0bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥94.4bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥58.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.21Tat 2023-12-31StandaloneAssets
Total assets¥1.27Tat 2022-12-31StandaloneAssets
Total assets¥1.25Tat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.21Tat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.16Tat 2019-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥132.5bnat 2023-12-31StandaloneLiabilities
Total liabilities¥208.2bnat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.08Tat 2023-12-31StandaloneNet assets
Net assets / equity¥1.06Tat 2022-12-31StandaloneNet assets
Net assets / equity¥1.07Tat 2021-12-31dStandaloneNet assets
Net assets / equity¥1.02Tat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥977.1bnat 2019-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥86.4bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥129.1bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥130.922023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥87.372022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥195.52021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥174.032020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥107.682019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥130.922023-01-01 → 2023-12-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥87.372022-01-01 → 2022-12-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥195.52021-01-01 → 2021-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥174.032020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥107.672019-01-01 → 2019-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1102023-01-01 → 2023-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002022-01-01 → 2022-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002021-01-01 → 2021-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1002020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1002019-01-01 → 2019-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,989.83at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,959.51at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,970.44at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,875.15at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,801.86at 2019-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio89.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio83.6%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio85.6%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.4%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE6.6%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE4.4%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE10.2%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE9.5%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
ROE6.0%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued557,835,617at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees151at 2023-12-31StandaloneNumber of employees
Employees147at 2022-12-31StandaloneNumber of employees
Employees137at 2021-12-31dStandaloneNumber of employees
Employees111at 2020-12-31dStandaloneNumber of employees
Employees104at 2019-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 61
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-01-01 → 2023-12-31¥12.5bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-12-31−¥42.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-12-31−¥42.7bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥50.4bn
Consumer Productsreportable segmentcapex2023-01-01 → 2023-12-31¥3.6bn
Consumer Productsreportable segmentemployeesat 2023-12-31621 pure
Consumer Productsreportable segmentrevenue2023-01-01 → 2023-12-31¥37.1bn
Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-12-31¥37.1bn
Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥14m
Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-12-31¥11.9bn
Nutraceuticalsreportable segmentcapex2023-01-01 → 2023-12-31¥105.4bn
Nutraceuticalsreportable segmentemployeesat 2023-12-318546 pure
Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-12-31¥483.5bn
Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-12-31¥483.3bn
Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥138m
Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-12-31¥33.6bn
Otherreportable segmentcapex2023-01-01 → 2023-12-31¥7.2bn
Otherreportable segmentemployeesat 2023-12-313603 pure
Otherreportable segmentrevenue2023-01-01 → 2023-12-31¥176.4bn
Otherreportable segmentrevenue external2023-01-01 → 2023-12-31¥133.8bn
Otherreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥42.6bn
Otherreportable segmentsegment profit2023-01-01 → 2023-12-31¥3.9bn
Pharmaceuticalsreportable segmentcapex2023-01-01 → 2023-12-31¥82.3bn
Pharmaceuticalsreportable segmentemployeesat 2023-12-3120084 pure
Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-12-31¥1.36T
Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-12-31¥1.36T
Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-12-31¥140.7bn
—segment totalcapex2023-01-01 → 2023-12-31¥198.5bn
—segment totalemployeesat 2023-12-3132854 pure
—segment totalrevenue2023-01-01 → 2023-12-31¥2.06T
—segment totalrevenue external2023-01-01 → 2023-12-31¥2.02T
—segment totalrevenue intersegment2023-01-01 → 2023-12-31¥42.7bn
—segment totalsegment profit2023-01-01 → 2023-12-31¥190.1bn
Reconciling Itemsreconcilingcapex2022-01-01 → 2022-12-31¥10.7bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-12-31−¥42.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-12-31−¥42.0bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥47.9bn
Consumer Productsreportable segmentcapex2022-01-01 → 2022-12-31¥3.3bn
Consumer Productsreportable segmentrevenue2022-01-01 → 2022-12-31¥35.9bn
Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-12-31¥35.9bn
Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-12-31¥26m
Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-12-31¥6.9bn
Nutraceuticalsreportable segmentcapex2022-01-01 → 2022-12-31¥15.0bn
Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-12-31¥437.0bn
Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-12-31¥437.0bn
Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-12-31¥32m
Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-12-31¥56.3bn
Otherreportable segmentcapex2022-01-01 → 2022-12-31¥9.3bn
Otherreportable segmentrevenue2022-01-01 → 2022-12-31¥169.2bn
Otherreportable segmentrevenue external2022-01-01 → 2022-12-31¥127.3bn
Otherreportable segmentrevenue intersegment2022-01-01 → 2022-12-31¥42.0bn
Otherreportable segmentsegment profit2022-01-01 → 2022-12-31¥11.9bn
Pharmaceuticalsreportable segmentcapex2022-01-01 → 2022-12-31¥101.0bn
Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-12-31¥1.14T
Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-12-31¥1.14T
Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-12-31¥123.1bn
—segment totalcapex2022-01-01 → 2022-12-31¥128.6bn
—segment totalrevenue2022-01-01 → 2022-12-31¥1.78T
—segment totalrevenue external2022-01-01 → 2022-12-31¥1.74T
—segment totalrevenue intersegment2022-01-01 → 2022-12-31¥42.0bn
—segment totalsegment profit2022-01-01 → 2022-12-31¥198.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 2,317
ItemContextValueUnit
Number of employeesPrior3YearInstant_NonConsolidatedMember111
Number of employeesPrior2YearInstant_NonConsolidatedMember137
Number of employeesPrior1YearInstant_NonConsolidatedMember147
Number of employeesCurrentYearInstant_NonConsolidatedMember151
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember16
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember17
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember18
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember18
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember23
Total shareholder returnPrior4YearInstant_NonConsolidatedMember1.109
Total shareholder returnPrior3YearInstant_NonConsolidatedMember1.028
Total shareholder returnPrior2YearInstant_NonConsolidatedMember0.995
Total shareholder returnPrior1YearInstant_NonConsolidatedMember1.047
Total shareholder returnCurrentYearInstant_NonConsolidatedMember1.291
Total return on share price indexPrior4YearInstant_NonConsolidatedMember1.181
Total return on share price indexPrior3YearInstant_NonConsolidatedMember1.268
Total return on share price indexPrior2YearInstant_NonConsolidatedMember1.430
Total return on share price indexPrior1YearInstant_NonConsolidatedMember1.395
Total return on share price indexCurrentYearInstant_NonConsolidatedMember1.789
Number of employeesCurrentYearInstant_jpcrp030000-asr_E21183-000PharmaceuticalsReportableSegmentMember20084
Average number of temporary workersCurrentYearInstant_jpcrp030000-asr_E21183-000PharmaceuticalsReportableSegmentMember1612
Number of employeesCurrentYearInstant_jpcrp030000-asr_E21183-000NutraceuticalsReportableSegmentMember8546
Average number of temporary workersCurrentYearInstant_jpcrp030000-asr_E21183-000NutraceuticalsReportableSegmentMember2298
Number of employeesCurrentYearInstant_jpcrp030000-asr_E21183-000ConsumerProductsReportableSegmentMember621
Average number of temporary workersCurrentYearInstant_jpcrp030000-asr_E21183-000ConsumerProductsReportableSegmentMember128
Number of employeesCurrentYearInstant_jpcrp030000-asr_E21183-000OtherReportableSegmentMember3603
Average number of temporary workersCurrentYearInstant_jpcrp030000-asr_E21183-000OtherReportableSegmentMember613
Number of employeesCurrentYearInstant_ReportableSegmentsMember32854
Average number of temporary workersCurrentYearInstant_ReportableSegmentsMember4651
Number of employeesCurrentYearInstant_CorporateSharedMember1534
Average number of temporary workersCurrentYearInstant_CorporateSharedMember509
Number of employeesCurrentYearInstant34388
Average number of temporary workersCurrentYearInstant5160
Number of employeesCurrentYearInstant_NonConsolidatedMember151
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember23
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember44.1
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember4.5
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember10456264JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember151
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember23
Number of employeesCurrentYearInstant_NonConsolidatedMember151
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember23
Research and development expenses research and development activitiesCurrentYearDuration307804000000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E21183-000PharmaceuticalsReportableSegmentMember292028000000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E21183-000NutraceuticalsReportableSegmentMember9874000000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E21183-000ConsumerProductsReportableSegmentMember663000000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E21183-000OtherReportableSegmentMember5238000000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration210988000000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration_jpcrp030000-asr_E21183-000PharmaceuticalsReportableSegmentMember82291000000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration_jpcrp030000-asr_E21183-000NutraceuticalsReportableSegmentMember105397000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass